PMID- 28945841
OWN - NLM
STAT- MEDLINE
DCOM- 20180705
LR  - 20180705
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 28
IP  - suppl_12
DP  - 2017 Dec 1
TI  - Antigen cross-presentation and T-cell cross-priming in cancer immunology and 
      immunotherapy.
PG  - xii44-xii55
LID - 10.1093/annonc/mdx237 [doi]
AB  - Dendritic cells (DCs) are the main professional antigen-presenting cells for 
      induction of T-cell adaptive responses. Cancer cells express tumor antigens, 
      including neoantigens generated by nonsynonymous mutations, but are poor for 
      antigen presentation and for providing costimulatory signals for T-cell priming. 
      Mounting evidence suggests that antigen transfer to DCs and their surrogate 
      presentation on major histocompatibility complex class I and II molecules 
      together with costimulatory signals is paramount for induction of viral and 
      cancer immunity. Of the great diversity of DCs, BATF3/IRF8-dependent conventional 
      DCs type 1 (cDC1) excel at cross-presentation of tumor cell-associated antigens. 
      Location of cDC1s in the tumor correlates with improved infiltration by CD8+ T 
      cells and tumor-specific T-cell immunity. Indeed, cDC1s are crucial for antitumor 
      efficacy using checkpoint inhibitors and anti-CD137 agonist monoclonal antibodies 
      in mouse models. Enhancement and exploitation of T-cell cross-priming by cDC1s 
      offer opportunities for improved cancer immunotherapy, including in vivo 
      targeting of tumor antigens to internalizing receptors on cDC1s and strategies to 
      increase their numbers, activation and priming capacity within tumors and 
      tumor-draining lymph nodes.
CI  - (c) The Author 2017. Published by Oxford University Press on behalf of the European 
      Society for Medical Oncology. All rights reserved. For permissions, please email: 
      journals.permissions@oup.com.
FAU - Sanchez-Paulete, A R
AU  - Sanchez-Paulete AR
AD  - Division of Immunology and Immunotherapy, Center for Applied Medical Research 
      (CIMA), University of Navarra, Pamplona.
FAU - Teijeira, A
AU  - Teijeira A
AD  - Division of Immunology and Immunotherapy, Center for Applied Medical Research 
      (CIMA), University of Navarra, Pamplona.
FAU - Cueto, F J
AU  - Cueto FJ
AD  - Immunobiology Laboratory, Fundacion Centro Nacional de Investigaciones 
      Cardiovasculares Carlos III (CNIC), Madrid.
AD  - Department of Biochemistry, Faculty of Medicine, Universidad Autonoma de Madrid, 
      Madrid.
FAU - Garasa, S
AU  - Garasa S
AD  - Division of Immunology and Immunotherapy, Center for Applied Medical Research 
      (CIMA), University of Navarra, Pamplona.
FAU - Perez-Gracia, J L
AU  - Perez-Gracia JL
AD  - University Clinic, University of Navarra, Pamplona, Spain.
AD  - CIBERONC, Madrid, Spain.
FAU - Sanchez-Arraez, A
AU  - Sanchez-Arraez A
AD  - Division of Immunology and Immunotherapy, Center for Applied Medical Research 
      (CIMA), University of Navarra, Pamplona.
FAU - Sancho, D
AU  - Sancho D
AD  - Immunobiology Laboratory, Fundacion Centro Nacional de Investigaciones 
      Cardiovasculares Carlos III (CNIC), Madrid.
FAU - Melero, I
AU  - Melero I
AD  - Division of Immunology and Immunotherapy, Center for Applied Medical Research 
      (CIMA), University of Navarra, Pamplona.
AD  - University Clinic, University of Navarra, Pamplona, Spain.
AD  - CIBERONC, Madrid, Spain.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Antigens, Neoplasm)
SB  - IM
EIN - Ann Oncol. 2017 Dec 1;28(suppl_12):xii74. PMID: 29253116
MH  - Animals
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/*immunology
MH  - Cross-Priming/immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Neoplasms/*immunology/*therapy
MH  - T-Lymphocytes/*immunology
OTO - NOTNLM
OT  - T cells
OT  - cancer immunotherapy
OT  - cross-presentation
OT  - cross-priming
OT  - dendritic cells
EDAT- 2017/09/26 06:00
MHDA- 2018/07/06 06:00
CRDT- 2017/09/26 06:00
PHST- 2017/09/26 06:00 [pubmed]
PHST- 2018/07/06 06:00 [medline]
PHST- 2017/09/26 06:00 [entrez]
AID - 4102224 [pii]
AID - 10.1093/annonc/mdx237 [doi]
PST - ppublish
SO  - Ann Oncol. 2017 Dec 1;28(suppl_12):xii44-xii55. doi: 10.1093/annonc/mdx237.